Sahlgrenska Science Park och UC Berkeley ingår partnerskap – ska hjälpa deeptech-bolag

Sahlgrenska Science Parks accelerator Co-Ax har ingått ett samarbete med UC Berkeleys innovationslabb för deeptech. Syftet med partnerskapet är att accelerera t...

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”

”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain market share compared to generics, and new biosimilars do not always lead to lower prices” writes...

Svensk toppforskare inom alzheimer värvas av Eli Lilly

En av Sveriges ledande alzheimerforskare, Oskar Hansson, rekryteras av läkemedelsjätten Eli Lilly och kommer att ta klivet över till USA.

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and l...

Orexo får USA-stöd för överdosläkemedel vid blandmissbruk

Uppsalabolaget Orexo har fått 8 miljoner dollar, motsvarande 75 miljoner kronor, av den amerikanska myndigheten Barda för att ta fram ett nasalt räddningsläkeme...

Flemingsberg – en växande nod för Life Science

Flemingsberg i södra Stockholm har länge varit hem för ett livskraftigt life science-kluster. Nu sker en tydlig acceleration då fler företag etablerar sig, sama...

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Meet us at Control 2025

Innovations that drive efficiency.

FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy

FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...

ZEISS supports the transition of spatial biology to clinical research

Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation.

ZEN core now available for all ZEISS scanning electron microscopes

Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.

FDA plans to replace animal testing with AI – “Paradigm shift”

The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...

Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”

The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from AB...

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.